Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

被引：6
作者：
Dempsey, Jacqueline M. [1 ]
Kidwell, Kelley M. [2 ]
Gersch, Christina L. [3 ]
Pesch, Andrea M. [3 ]
Desta, Zeruesenay [4 ]
Storniolo, Anna Maria [4 ]
Stearns, Vered [5 ]
Skaar, Todd C. [4 ]
Hayes, Daniel F. [3 ]
Henry, N. Lynn [3 ]
Rae, James M. [3 ]
Hertz, Daniel L. [1 ]
机构：
[1] Univ Michigan, Coll Pharm, Dept Clin Pharm, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Med Sch, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[4] Indiana Univ, Dept Med, Indianapolis, IN 46202 USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA
来源：
PHARMACOGENOMICS | 2019年 / 20卷 / 08期
关键词：
breast cancer; exemestane; letrozole; pharmacogenomics; SLCO1B1; GENOME-WIDE ASSOCIATION; POSTMENOPAUSAL WOMEN; ANASTROZOLE; TAMOXIFEN; EFFICACY; AROMATIZATION; PREDICTORS; METABOLISM; ESTRADIOL; VARIANTS;
D O I：
10.2217/pgs-2019-0020
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: This study tested for associations between SLCO1B1 polymorphisms and circulating estrogen levels in women with breast cancer treated with letrozole or exemestane. Patients & methods: Postmenopausal women with hormone-receptor positive breast cancer were genotyped for SLCO1B1*5 (rs4149056) and rs10841753. Pretreatment and on-treatment plasma estrogens and aromatase inhibitor (AI) concentrations were measured. Regression analyses were performed to test for pharmacogenetic associations with estrogens and drug concentrations. Results:SLCO1B1*5 was associated with elevated pretreatment estrone sulfate and an increased risk of detectable estrone concentrations after 3months of AI treatment. Conclusion: These findings suggest SLCO1B1 polymorphisms may have an effect on estrogenic response to AI treatment, and therefore may adversely impact the anticancer effectiveness of these agents.
引用
收藏
页码：571 / 580
页数：10
相关论文
共 32 条
  • [1] Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer
    Borrie, Adrienne E.
    Rose, Rhiannon V.
    Choi, Yun-Hee
    Perera, Francisco E.
    Read, Nancy
    Sexton, Tracy
    Lock, Michael
    Vandenberg, Theodore A.
    Hahn, Karin
    Dinniwell, Robert
    Younus, Jawaid
    Logan, Diane
    Potvin, Kylea
    Yaremko, Brian
    Yu, Edward
    Lenehan, John
    Welch, Stephen
    Tyndale, Rachel F.
    Teft, Wendy A.
    Kim, Richard B.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (02) : 371 - 379
  • [2] Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers
    Brown, Susan B.
    Hankinson, Susan E.
    [J]. STEROIDS, 2015, 99 : 8 - 10
  • [3] Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
    Cuzick, Jack
    Sestak, Ivana
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Dowsett, Mitch
    Forbes, John F.
    [J]. LANCET ONCOLOGY, 2010, 11 (12) : 1135 - 1141
  • [4] Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age
    Desta, Z.
    Kreutz, Y.
    Nguyen, A. T.
    Li, L.
    Skaar, T.
    Kamdem, L. K.
    Henry, N. L.
    Hayes, D. F.
    Storniolo, A. M.
    Stearns, V.
    Hoffmann, E.
    Tyndale, R. F.
    Flockhart, D. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (05) : 693 - 700
  • [5] Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606
  • [6] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
    Dowsett, M.
    Forbes, J. F.
    Bradley, R.
    Ingle, J.
    Aihara, T.
    Bliss, J.
    Boccardo, F.
    Coates, A.
    Coombes, R. C.
    Cuzick, J.
    Dubsky, P.
    Gnant, M.
    Kaufmann, M.
    Kilburn, L.
    Perrone, F.
    Rea, D.
    Thuerlimann, B.
    van de Velde, C.
    Pan, H.
    Peto, R.
    Davies, C.
    Gray, R.
    Baum, M.
    Buzdar, A.
    Sestak, I.
    Markopoulos, C.
    Fesl, C.
    Jakesz, R.
    Colleoni, M.
    Gelber, R.
    Regan, M.
    von Minckwitz, G.
    Snowdon, C.
    Goss, P.
    Pritchard, K.
    Anderson, S.
    Costantino, J.
    Mamounas, E.
    Ohashi, Y.
    Watanabe, T.
    Bastiaannet, E.
    [J]. LANCET, 2015, 386 (10001) : 1341 - 1352
  • [7] SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER plus breast cancer: genome-wide association studies of the estrone pathway
    Dudenkov, Tanda M.
    Ingle, James N.
    Buzdar, Aman U.
    Robson, Mark E.
    Kubo, Michiaki
    Ibrahim-zada, Irada
    Batzler, Anthony
    Jenkins, Gregory D.
    Pietrzak, Tracy L.
    Carlson, Erin E.
    Barman, Poulami
    Goetz, Matthew P.
    Northfelt, Donald W.
    Moreno-Aspita, Alvaro
    Williard, Clark V.
    Kalari, Krishna R.
    Nakamura, Yusuke
    Wang, Liewei
    Weinshilboum, Richard M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (01) : 189 - 199
  • [8] Estrogen Metabolism and Risk of Breast Cancer in Postmenopausal Women
    Fuhrman, Barbara J.
    Schairer, Catherine
    Gail, Mitchell H.
    Boyd-Morin, Jennifer
    Xu, Xia
    Sue, Laura Y.
    Buys, Saundra S.
    Isaacs, Claudine
    Keefer, Larry K.
    Veenstra, Timothy D.
    Berg, Christine D.
    Hoover, Robert N.
    Ziegler, Regina G.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (04) : 326 - 339
  • [9] Geisler J, 1998, CLIN CANCER RES, V4, P2089
  • [10] Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study
    Geisler, J
    Haynes, B
    Anker, G
    Dowsett, M
    Lonning, PE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) : 751 - 757
1234